Navigation Links
Reportlinker Adds Antiemetics: Technologies and Global Markets
Date:12/14/2010

NEW YORK, Dec. 14, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antiemetics: Technologies and Global Markets

http://www.reportlinker.com/p0341186/Antiemetics-Technologies-and-Global-Markets.html

The global market for antiemetics was nearly $2.4 billion in 2009.  There was a little setback seen in 2009 in the 5-HT3 category due to weakened economy and competition within brands and generics.  The market for antiemetic products is expected to reach $2.5 billion by the end of 2010 and $3.6 billion by 2015, reflecting a 7.4% compound annual growth rate (CAGR).

Although 5-HT3 antagonists have seen a decline in 2009, this category holds about half of the market. This sector is valued at an estimated $1 billion in 2010 and is expected to increase at a 3.6% compound annual growth rate (CAGR) between 2010 and 2015 to reach $1.3 billion in 2015.

NK1 receptor and dopamine antagonist and anticholinergics will experience the most growth over the forecast period. This sector is worth an estimated $582 million in 2010 and is expected to reach more than $1 billion by 2015, a 13.3% compound annual growth rate (CAGR).INTRODUCTION 

STUDY OBJECTIVESBCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for antiemetic agents. The key objective is to present a comprehensive analysis of the current market and its future direction and the antiemetics market as an important agent as adjunct therapy for cancer patients and also other therapeutic arenas to control emesis.

This report explores present and future strategies within the antiemetic market, reason for emesis, and types of antiemetic agents used to control nausea or vomiting. The improvisation of the market, and the setbacks and the needs of the market are discussed in this report. The causes of emesis, usage of antiemetics and the types of products available to treat nausea and vomiting of each category of antiemetics are also portrayed in this report.

A detailed analysis of the antiemetic industry structure has been conducted. The revenues are broken down by region. Sales figures are estimated for the 5 year period from the end of 2010 through 2015.

Applications for antiemetics are also discussed separately in the report, with emphasis on the usage in chemotherapy-induced nausea and vomiting (CINV), post-radiotherapy nausea and vomiting, and post-operative nausea and vomiting (PONV), etc. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDYEmesis itself is not a disease but is stressful enough to discourage a patient, especially a patient dealing with cancer therapies. The antiemetics market has seen advancement in modern medicine. R&D spending, along with increasing competition, patent expiries, new technologies, and an international marketplace are directing this new direction. The antiemetics market has seen almost a constant growth except some setbacks in 5-HT2 category in 2009, due to the general economic downturn, but new advances and the need for good pharmacological activity of antiemetic products are influencing the market to grow. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each system/ technology in light of the new technologies, growing competition, and changing customer needs.

INTENDED AUDIENCEThis study contributes to the areas of market growth in the antiemetic industry from the point of view of manufacturers and users. Biotechnological companies, physicians, the pharmaceutical and biopharmaceutical industries, hospitals, and research institutes will find this study to be of interest.

SCOPE OF THE STUDYThe scope of this study encompasses the biotechnology, pharmaceutical, and medical markets. BCC analyzes each market and its applications by its need for development of new medications, regulatory environment, technology involved, market projections, and market share. Technological issues include the latest trends and developments.

METHODOLOGYBoth primary and secondary research methodologies were used in preparing this market research report. BCC conducted a comprehensive search of the literature, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with various analytical/chemical/pharmaceutical/biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCESMany companies within the industry were contacted to obtain data for this study. Included were manufacturers and end users of biopharmaceutical and pharmaceutical products, through their production, research, and contract manufacturing/research lines. Data were gathered from various industry sources. BCC spoke with officials and physicians within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.

ABOUT THE AUTHORShalini S. Dewan holds a master's degree in pharmaceutical chemistry. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are MST034C Reagents for Chromatography; IAS004B Spectroscopy, An Enduring Market; PHM006G Advanced Drug Delivery Systems: New Developments, New Technologies; PHM040A Orthopedic Drugs, Implants and Devices; HLC040C Medical Imaging Reagents and Analysis Equipment; PHM047A Pharmaceutical Regulatory Industry; and BIO014F The Dynamic Media, Sera and Reagent Market in Biotechnology.

Chapter- 1: INTRODUCTION -- Complimentary

STUDY OBJECTIVES 1

REASONS FOR DOING THIS STUDY 1

INTENDED AUDIENCE 2

SCOPE OF THE STUDY 2

METHODOLOGY 2

INFORMATION SOURCES 2

ABOUT THE AUTHOR 3

RELATED BCC RESEARCH REPORTS 3

BCC ONLINE SERVICES 3

DISCLAIMER 4

Chapter-2: EXECUTIVE SUMMARY

EXECUTIVE SUMMARY 5

SUMMARY TABLE WORLDWIDE REVENUE OF ANTIEMETICS, THROUGH 2015 ($ MILLIONS) 6

SUMMARY FIGURE WORLDWIDE REVENUE OF ANTIEMETICS, 2008-2015 ($ MILLION) 6

Chapter-3: OVERVIEW

STAGES IN NAUSEA AND VOMITING 7

TYPES OF EMESIS 8

RELATIONSHIP BETWEEN RECEPTORS AND NAUSEA 8

THE GI TRACT 9

THE CHEMORECEPTOR TRIGGER ZONE (CTZ) 9

THE VESTIBULAR APPARATUS 9

THE CEREBRAL CORTEX 10

HISTORY 10

HISTORY OF PATHOPHYSIOLOGY 10

HISTORY OF ANTIEMETIC THERAPY 10

TABLE 1  HISTORY OF ANTIEMETIC THERAPY 10

TABLE 1 (CONTINUED) 11

TABLE 2 HISTORY OF SEROTONIN AND 5-HT RECEPTORS 11

TABLE 3 HISTORY OF TACHYKININS AND NEUROKININ RECEPTORS 12

TABLE 4 HISTORY OF CORTICOSTEROIDS 12

TABLE 5 HISTORY OF DOPAMINE AND DOPAMINE RECEPTORS 12

CAUSES OF EMESIS AND ITS THERAPY 13

VESTIBULAR INVOLVEMENT 13

OBSTRUCTION 14

MIND 14

INFECTION, IRRITATION, AND INFLAMMATION 15

TOXINS 15

TABLE 6 CAUSES OF EMESIS AND THE THERAPY INVOLVED 16

Chapter-4: TYPE OF ANTIEMETIC DRUGS

TYPES OF ANTIEMETIC DRUGS 17

5-HTD— RECEPTOR ANTAGONISTS 17

TABLE 7 5-HTD— RECEPTOR ANTAGONISTS DRUG PRODUCTS AS ANTIEMETICS 18

NK1 RECEPTOR ANTAGONISTS 18

TABLE 8 5NK1 RECEPTOR ANTAGONISTS DRUG PRODUCTS AS ANTIEMETICS 19

ANTIHISTAMINES (HI ANTIHISTAMINE RECEPTOR ANTAGONISTS): 19

TABLE 9 ANTIHISTAMINES DRUG PRODUCTS AS ANTIEMETICS 19

TABLE 9 (CONTINUED) 20

DOPAMINE ANTAGONISTS 20

TABLE 10 DOPAMINE ANATAGONISTS, DRUG PRODUCTS AS ANTIEMETICS 21

STEROID-CORTICOSTEROIDS 21

TABLE 11 STEROIDS-CORTICOSTEROIDS, DRUG PRODUCTS AS ANTIEMETICS 22

CANNABINOIDS 22

TABLE 12 CANNABINOIDS, DRUG PRODUCTS AS ANTIEMETICS 23

BENZODIAZEPINES 23

TABLE 13 BENZODIAZEPINES, DRUG PRODUCTS AS ANTIEMETICS 24

ANTICHOLINERGICS 25

TABLE 14 ANTICHOLENERGIC DRUG PRODUCTS AS ANTIEMETICS 25

OTHERS 25

TABLE 15 OTHER PRODUCTS AS ANTIEMETICS 26

TABLE 16 NON-PHARMACEUTICAL THERAPIES 26

TABLE 16 (CONTINUED) 27

Chapter-5: REGULATORY ASPECTS

TABLE 17 APPROVALS OF ANTIEMETICS, 2007 TO APRIL 2010 28

TABLE 17 (CONTINUED) 29

TABLE 17 (CONTINUED) 30

TABLE 17 (CONTINUED) 31

TABLE 17 (CONTINUED) 32

TABLE 17 (CONTINUED) 33

TABLE 18 REGULATORY CHANGES OF ANTIEMETICS, 2007 TO APRIL 2010, BY ACTIVE INGREDIENT 34

TABLE 18 (CONTINUED) 35

TABLE 18 (CONTINUED) 36

TABLE 19 SAFETY ALERTS FOR ANTIEMETICS, 2007 TO APRIL 2010, BY ACTIVE INGREDIENT 36

TABLE 19 (CONTINUED) 37

REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS 37

REGULATORY UPDATES: APPROVAL, … (CONTINUED) 38

Chapter-6: INDUSTRY STRUCTURE

MANUFACTURERS/PRODUCTS FOR ANTIEMETICS 39

TABLE 20 LEADING MANUFACTURERS OF 5-HT3 RECEPTOR ANTAGONISTS 39

TABLE 20 (CONTINUED) 40

TABLE 21 LEADING MANUFACTURERS OF NK-1 RECEPTOR ANTAGONISTS 40

TABLE 22 LEADING MANUFACTURERS OF H1 RECEPTOR ANTAGONISTS 40

TABLE 22 (CONTINUED) 41

TABLE 23 LEADING MANUFACTURERS OF DOPAMINE ANTAGONISTS 41

TABLE 23 (CONTINUED) 42

TABLE 24 LEADING MANUFACTURERS/ SUPPLIERS OF STEROIDS-CORTICOSTEROIDS 42

TABLE 25 LEADING MANUFACTURERS/ SUPPLIERS OF CANNABINOIDS 43

TABLE 26 LEADING MANUFACTURERS/ SUPPLIERS OF BENZODIAZEPINES 43

TABLE 27 LEADING MANUFACTURERS/ SUPPLIERS OF ANTICHOLINERGICS 43

MARKET SHARES OF INDUSTRY LEADERS 44

5-HT3 RECEPTOR ANATAGONISTS 44

TABLE 28 WORLDWIDE MARKET SHARES OF 5-HT3 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%) 44

FIGURE 1 WORLDWIDE MARKET SHARES OF 5-HT3 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%) 45

NK-1 RECEPTOR ANATAGONISTS 45

TABLE 29 WORLDWIDE MARKET SHARES OF NK-1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%) 45

H1 RECEPTOR ANATAGONISTS 46

TABLE 30 WORLDWIDE MARKET SHARES OF H1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%) 46

FIGURE 2 WORLDWIDE MARKET SHARES OF H1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%) 47

DOPAMINE ANATAGONISTS 47

TABLE 31 WORLDWIDE MARKET SHARES OF DOPAMINE ANTAGONISTS USED AS ANTIEMETICS, 2009 (%) 47

FIGURE 3 WORLDWIDE MARKET SHARES OF DOPAMINE ANTAGONISTS USED AS ANTIEMETICS, 2009 (%) 48

STEROIDS-CORTICOSTEROIDS 48

TABLE 32 WORLDWIDE MARKET SHARES OF STEROIDS-CORTICOSTEROIDS USED AS ANTIEMETICS, 2009 (%) 48

FIGURE 4 WORLDWIDE MARKET SHARES OF STEROIDS-CORTICOSTEROIDS USED AS ANTIEMETICS, 2009 (%) 49

CANNABINOIDS 49

TABLE 33 WORLDWIDE MARKET SHARES OF CANNABINOIDS USED AS ANTIEMETICS, 2009 (%) 49

FIGURE 5 WORLDWIDE MARKET SHARES OF CANNABINOIDS USED AS ANTIEMETICS, 2009 (%) 50

BENZODIAZEPINES 50

TABLE 34 WORLDWIDE MARKET SHARES OF BENZODIAZEPINES USED AS ANTIEMETICS, 2009 (%) 50

FIGURE 6 WORLDWIDE MARKET SHARES OF BENZODIAZEPINES USED AS ANTIEMETICS, 2009 (%) 51

ANTICHOLINERGICS 51

TABLE 35 WORLDWIDE MARKET SHARES OF ANTICHOLINERGICS USED AS ANTIEMETICS, 2009 (%) 51

FIGURE 7 WORLDWIDE MARKET SHARES OF ANTICHOLINERGICS USED AS ANTIEMETICS, 2009 (%) 52

Chapter-7: NEW DEVELOPMENTS

NEW DEVELOPMENTS 53

TABLE 36 WORLDWIDE NEW DEVELOPED DRUGS SINCE 2003 54

TABLE 37 PIPELINE ANTIEMETICS 55

TABLE 37 (CONTINUED) 56

RECENT UPDATES FROM THE ANTIEMETIC WORLD 56

RECENT UPDATES FROM THE … (CONTINUED) 57

RECENT UPDATES FROM THE … (CONTINUED) 58

Chapter-8: MARKET ANALYSIS

5-HT3 RECEPTOR ANTAGONISTS 59

MARKET OVERVIEW 60

Market Overview (Continued) 61

MARKET REVENUE 62

TABLE 38 WORLDWIDE MARKET FOR 5-HT3 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 62

FIGURE 8 WORLDWIDE MARKET FOR 5-HT3 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 63

NK1 RECEPTOR ANTAGONISTS 63

MARKET OVERVIEW 64

MARKET REVENUE 64

TABLE 39 WORLDWIDE MARKET FOR NK-1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 65

FIGURE 9 WORLDWIDE MARKET FOR NK-1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 65

H1 RECEPTOR ANTAGONISTS 66

MARKET OVERVIEW 66

MARKET REVENUE 67

TABLE 40 WORLDWIDE MARKET FOR H1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 67

FIGURE 10 WORLDWIDE MARKET FOR H1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 67

DOPAMINE ANTAGONISTS 68

MARKET OVERVIEW 68

MARKET REVENUE 69

TABLE 41 WORLDWIDE MARKET FOR DOPAMINE ANTAGONISTS USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 69

FIGURE 11 WORLDWIDE MARKET FOR DOPAMINE ANTAGONISTS USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 70

STEROIDS -CORTICOSTEROIDS 70

MARKET OVERVIEW 70

MARKET REVENUE 71

TABLE 42 WORLDWIDE MARKET FOR STEROIDS-CORTICOSTEROIDS USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 72

FIGURE 12 WORLDWIDE MARKET FOR STEROIDS-CORTICOSTEROIDS USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 72

CANNABINOIDS 72

MARKET OVERVIEW 73

MARKET REVENUE 73

TABLE 43 WORLDWIDE MARKET FOR CANNABINOIDS USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 74

FIGURE 13 WORLDWIDE MARKET FOR CANNABINOIDS USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 74

BENZODIAZEPINES 74

MARKET OVERVIEW 75

MARKET REVENUE 75

TABLE 44 WORLDWIDE MARKET FOR BENZODIAZEPINES USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 76

FIGURE 14 WORLDWIDE MARKET FOR BENZODIAZEPINES USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 76

ANTICHOLINERGICS 76

MARKET OVERVIEW 77

MARKET REVENUE 77

TABLE 45 WORLDWIDE MARKET FOR ANTICHOLINERGICS USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 77

FIGURE 15 WORLDWIDE MARKET FOR ANTICHOLINERGIC USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 78

MARKET SHARES 78

TABLE 46 WORLDWIDE ANTIEMETICS AGENTS MARKET SHARES BY REGION, 2009 (%) 78

FIGURE 16 WORLDWIDE ANTIEMETICS AGENTS MARKET SHARES BY REGION, 2009 (%) 79

Chapter-9: MARKET BY APPLICATIONS

MARKET SHARE OF APPLICATIONS 80

TABLE 47 WORLDWIDE ANTIEMETIC MARKET SHARES, BY APPLICATION, 2009 (%) 81

FIGURE 17 WORLDWIDE ANTIEMETICS MARKET SHARES, BY APPLICATION, 2009 (%) 81

CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) 81

CHEMOTHERAPY-INDUCED NAUSEA …(CONTINUED) 82

TABLE 48 ANTIMETIC THERAPIES FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING 83

MARKET REVENUE 83

TABLE 49 GLOBAL SALES OF ANTIEMETIC DRUGS IN CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, THROUGH 2015 ($ MILLIONS) 84

FIGURE 18 GLOBAL SALES OF ANTIEMETIC DRUGS IN CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2008-2015 ($ MILLIONS) 84

NAUSEA AND VOMITING DUE TO MOTION SICKNESS 85

TABLE 50 ANTIEMETIC THERAPIES FOR NAUSEA AND VOMITING DUE TO MOTION SICKNESS 85

MARKET REVENUE 86

TABLE 51 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN MOTION SICKNESS, THROUGH 2015 ($ MILLIONS) 86

FIGURE 19 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN MOTION SICKNESS, 2008-2015 ($ MILLIONS) 86

POSTOPERATIVE NAUSEA AND VOMITING 87

TABLE 52 ANTIEMETIC THERAPIES FOR POSTOPERATIVE NAUSEA AND VOMITING 87

MARKET REVENUE 87

TABLE 53 GLOBAL SALES OF ANTIEMETIC DRUGS IN POSTOPERATIVE NAUSEA AND VOMITING, THROUGH 2015 ($ MILLIONS) 88

FIGURE 20 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN POSTOPERATIVE NAUSEA AND VOMITING, THROUGH 2015 ($ MILLIONS) 88

POST-RADIATION NAUSEA AND VOMITING 88

TABLE 54 ANTIEMETIC THERAPIES FOR RADIOTHERAPY INDUCED NAUSEA AND VOMITING 89

MARKET REVENUE 90

TABLE 55 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN RADIOTHERAPY-INDUCED NAUSEA AND VOMITING, THROUGH 2015 ($ MILLIONS) 90

FIGURE 21 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN RADIOTHERAPY INDUCED NAUSEA AND VOMITING, 2008-2015 ($ MILLIONS) 91

ACUTE GASTROENTERITIS 91

TABLE 56 ANTIEMETIC THERAPIES FOR ACUTE GASTROENTERITIS VOMITING 92

MARKET REVENUE 92

TABLE 57 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN ACUTE GASTROENTERITIS, THROUGH 2015 ($ MILLIONS) 92

FIGURE 22 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN ACUTE GASTROENTERITIS, 2008-2015 ($ MILLIONS) 93

OTHER CONDITIONS 93

TABLE 58 ANTIEMETIC THERAPIES FOR OTHER CONDITIONS 94

MARKET REVENUE 94

TABLE 59 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN OTHER CONDITIONS, THROUGH 2015 ($ MILLIONS) 94

FIGURE 23 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN OTHER CONDITIONS, THROUGH 2015 ($ MILLIONS) 95

Chapter-10: PATENT ANALYSIS

PATENTS BY YEAR 96

TABLE 60 NUMBER OF SIGNIFICANT ANTIEMETIC PATENTS BY YEAR, 2006–2010 97

FIGURE 24 NUMBER OF ANTIEMETIC PATENTS BY YEAR, 2006–2010 97

FIGURE 25 NUMBER OF ANTIEMETIC PATENTS BY YEAR, 2006–2010 (%) 98

PATENTS BY MODE OF ADMINISTRATION 98

TABLE 61 PATENTS BY MODE/ ROUTE OF ADMINISTRATION, 2006–2010 98

FIGURE 26 PATENTS BY MODE/ ROUTE OF ADMINISTRATION, 2006–2009 99

PATENTS BY TYPE/CATEGORY 99

TABLE 62 PATENTS BY TYPE/ CATEGORY FOR ANTIEMETICS, 2006–2010 100

FIGURE 27 PATENTS BY TYPE/CATEGORY FOR ANTIEMETICS, 2006–2009 101

PATENTS BY COMPANY 101

TABLE 63 NUMBER OF U.S. PATENTS BY COMPANY FOR ANTIEMETICS, 2006–2010 102

FIGURE 28 NUMBER OF U.S. PATENTS BY COMPANY FOR ANTIEMETICS, 2006–2010 102

PATENTS BY COUNTRY 103

TABLE 64 NUMBER OF U.S. PATENTS BY COUNTRY FOR ANTIEMETICS, 2006–2010 103

FIGURE 29 NUMBER OF U.S. PATENTS BY COUNTRY FOR CONTRAST AGENTS, 2006–2010 103

TABLE 65
PATENT SHARES BY COUNTRY FOR ANTIEMETICS, 2006–2010 (%) 104

FIGURE 3
PATENT SHARES BY COUNTRY FOR ANTIEMETICS, 2006–2010 (%) 104

ANTIEMETICS PATENTS WORLDWIDE 104

TABLE 66 NUMBER OF ANTIEMETIC PATENTS ISSUED BY DIFFERENT PATENT ORGANIZATIONS WORLDWIDE, 2006–2010 105

FIGURE 31 ANTIEMETIC PATENTS ISSUED BY DIFFERENT PATENT ORGANIZATIONS WORLDWIDE, 2006–2010 106

PATENTS BY ASSIGNEE (WORLDWIDE) 106

TABLE 67 PATENTS BY ASSIGNEE (WORLDWIDE) FOR ANTIEMETICS, 2006–2010 106

FIGURE 32 PATENTS BY ASSIGNEE (WORLDWIDE) FOR ANTIEMETICS, 2006–2010 107

Chapter-11: CURRENT SITUATION OF ANTIEMETICS MARKET

MARKET RESTRAINTS 108

COMPETITION 108

COST OF THE DRUGS 109

PATENTS EXPIRATIONS 109

TABLE 68 PATENT EXPIRATIONS 109

GROWTH FACTORS 110

LIFE EXPECTANCY 110

PATENT PROTECTION 110

DRUGS PORTFOLIO MANAGEMENT 110

FUTURE OF ANTIEMETICS MARKET 110

TABLE 69 COMPARISON OF I AND II GENERATION 5-HT3 RECEPTOR ANTAGONISTS 111

Chapter-12: COMPANY PROFILES

ABBOTT LABS 112

ACTAVIS 113

AKORN, INC. AND AKORN STRIDES 113

APOTEX INC. 114

APP PHARMACEUTICALS 114

ASTELLAS PHARMA GMBH 115

AUROBINDO PHARMA 115

BAXTER HEALTHCARE CORPORATION 116

BEDFORD LABORATORIES 117

BIOVAIL PHARMACEUTICALS, INC. 117

CADILA PHARMACEUTICALS LTD. 118

CIPLA LTD. 119

CLARIS LIFESCIENCES 119

CORE PHARMA LLC 120

CYPRESS PHARMACEUTICAL, INC. 120

DR. REDDY'S LABORATORIES LTD. 121

EISAI INC. 122

GLAND PHARMA LTD 122

GLAXO SMITHKLINE 123

GLENMARK GENERICS LIMITED 124

GROUP TECHNICALE-FARMOZ S.A 124

G & W LABS 125

HAMELN PHARMACEUTICALS LTD. 125

HAWTHORN PHARMACEUTICALS, INC. 126

HELSINN HEALTHCARE SA/EISAI 126

HETERO DRUGS LIMITED 127

HIKMA FARMACEUTICA PLC 127

HOSPIRA 128

IMPAX LABS 128

INSIGHT PHARMACEUTICALS CORP. 129

IPCA LABS LTD. 130

JANSSEN (A DIVISION OF ORTHO MCNEIL JANSSEN, J & J) 130

KING PHARMACEUTICALS INC. 131

KVK-TECH, INC. 132

LUITPOLD PHARMACEUTICALS, INC. 132

MANX PHARMA LTD. 133

MEDA PHARMACEUTICALS 134

MERCK & CO., INC. 134

MYLAN 135

NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD. 136

NOVELL PHARMACEUTICAL LABORATORIES 136

PAR PHARMACEUTICALS 137

PFIZER INC. 138

PIRAMAL HEALTHCARE LIMITED 138

PLIVA HRVATSKA DOO (TEVA GROUP COMPANY) 139

PROSTRAKAN GROUP PLC 139

ROCHE LABORATORIES (F. HOFFMANN-LA ROCHE AG) 140

ROSEMONT PHARMACEUTICALS LTD. 141

SALIX PHARMACEUTICALS INC. 142

SANOFI AVENTIS US 142

SATO PHARMACEUTICALS 143

SCHWARZ PHARMA (UCB SUBSIDIARY) 144

SOLVAY PHARMACEUTICALS (UNIMED/ABBOTT) 144

STRATIVA PHARMACEUTICALS 145

SUN PHARMACEUTICAL INDUSTRIES LTD. 145

TARO PHARMACEUTICAL INDUSTRIES LTD. 146

TEVA PHARMACEUTICAL INDUSTRIES LTD. 146

TORRENT PHARMACEUTICALS 147

WALLACE PHARMACEUTICALS LTD. 148

WATSON PHARMACEUTICALS, INC. 148

WOCKHARDT USA LLC 149

ZYDUS CADILA 149

ZYDUS PHARMS USA 150

Chapter-13: ABBREVIATIONS

TABLE 70 ABBREVIATIONS 151

TABLE 70 (CONTINUED) 152

To order this report:Drug and Medication Industry: Antiemetics: Technologies and Global Markets

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Anti-Counterfeiting Packaging Technologies in the Global Pharmaceutical and Food Industries
2. Reportlinker Adds European Markets for Dental Bone Graft Substitutes, Dental Membranes and Tissue Engineering 2011
3. Reportlinker Adds U.S. Market for Patient Monitoring Devices 2011
4. Reportlinker Adds European Markets for Video, High-Tech and Integrated OT Equipment 2011
5. Reportlinker Adds Corporate Strategies in Consumer Health 2010
6. Reportlinker Adds Allergic Conjunctivitis - Pipeline Assessment and Market Forecasts to 2017
7. Reportlinker Adds Chinese Markets for Drug Delivery System
8. Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020
9. Reportlinker Adds Asia-Pacific Endoscopy Devices Market Outlook to 2016
10. Reportlinker Adds North America Neurology Devices Market Outlook to 2016
11. Reportlinker Adds Europe Cardiovascular Devices Market Outlook to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
Breaking Medicine News(10 mins):